E-MISAGO – the largest ongoing real life registry of Misago SX nitinol stent in daily use – Clinical Outcome at 1 year (original) (raw)

Abstract

Background: Interim analysis of the first 1000 patients treated with Misago RX nitinol stent in iliac and femoropopliteal arteries at 1 year follow-up. Methods: e-MISAGO enrolled more than 3000 patients treated with the Misago stent in 94 European centers. All clinical data collected through an EDC platform are fully monitored and all reported serious adverse events are independently adjudicated. Primary safety (at 30 days) and efficacy endpoint (at 1 year) match the VIVA criteria. Results: Patients (68% male) were 67±10 years old, 63% were smokers, 36% had diabetes mellitus (36% IDDM), 46% had hypercholesterolemia and 76% arterial hypertension. Patients had history of previous coronary artery disease in 32% of the cases and 14% previous myocardial infarction. Claudication and symptomatic ischemia concerned 99% and 96% of the patient population. Mean lesion length was 64.5±59.0 mm, with reference vessel diameter 6.3± 1.3 mm. Mean lesions' stenosis was 88.6±12.4% and 43.3% of the...

Stefan Schulte hasn't uploaded this paper.

Let Stefan know you want this paper to be uploaded.

Ask for this paper to be uploaded.